The Union Health Ministry has proposed new amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at simplifying the drug approval process. This was recently in the news because the government has invited public comments on the amendments to the NDCT rules.
Timeline
- NDCT Rules, 2019: Reduced Approval timelines and clarified the safety Protocols.
- 2023 Change: Drugs approved in the US, UK, EU, Japan, Canada, and Australia were also approved in India without local trials.
- Proposed Amendments: New rules have been proposed to waive local trials for specific drug formulations.
Why are the New Drug Approval Rules important?
- This could enable the fast-track of research and adoption of therapies for TB, Cancer, autoimmune diseases, and Alzheimer’s disease.
- This will support India’s aspiration to move beyond Generic Drugs and vaccines towards cutting-edge R&D.
Concerns raised by medical practitioners
- Risk of bypassing local trials in a genetically diverse country like India.
- There is also a lack of adequate testing mechanisms and regulatory manpower.
- Need for Stronger post-marketing drug surveillance to ensure safety.
Way Forward
- Our Government needs to strengthen Regulatory Capacity and Quality Monitoring.
- We need to build global Collaborations between India and Foreign Laboratories.
- Most importantly, we need to balance speed with the safety of Patients.
- We need to ensure transparent public consultations before finalising amendments.
Static Part
Regulator: Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health & Family Welfare.
Legal Basis: Drugs and Cosmetics Act, 1940, and NDCT Rules, 2019.
Phases of Clinical Trials:
- Phase I: Safety (small group of healthy volunteers).
- Phase II: Efficacy & side effects (patients).
- Phase III: Larger population, compared with standard treatments.
- Phase IV: Post-marketing surveillance.
India’s Position: Known as the “Pharmacy of the World” for generics and vaccines, but lagging in new drug discovery & R&D capacity.
Correlation with Syllabus
UPSC Syllabus
Prelims (General Studies Paper I):
GS Paper II:
Prelims (General Studies):
Paper II:
Prelims (General Studies Paper I):
- General Science → Drug discovery, biotechnology applications.
- Current Events → Regulatory reforms in the pharma sector.
- Indian Polity & Governance → Role of CDSCO, Ministry of Health & Family Welfare.
GS Paper II:
- Government policies and interventions in the health sector.
- Issues relating to the development and management of health services.
- Role of regulatory bodies in protecting patient welfare.
- Developments in Science & Technology and their applications in everyday life.
- Achievements of Indians in science & technology; indigenization of technology.
- Biotechnology and issues relating to intellectual property rights, pharma R&D.
Prelims (General Studies):
- Science & Technology → New inventions in medicine and health, application of biotechnology.
- Indian Polity → Welfare schemes of the Government of India in the health sector.
- Current Events → National scientific developments, medical innovations, government policies.
Paper II:
- Social Justice and Welfare Schemes – Health Sector Governance.
- Policy measures for vulnerable sections (patients & trial participants).
- Developments in science and technology in India.
- Role of biotechnology and the pharmaceutical industry in economic development.
- Health-related innovations and India’s contribution to global medicine.
Quiz
[ays_quiz id=’5′]
📌 Related Posts: